{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:34:40Z","timestamp":1772724880623,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.xphs.2026.104164","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T07:40:03Z","timestamp":1768376403000},"page":"104164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of the formation of (sub)visual particles in ready-to-administer trastuzumab infusion bags during transport from the hospital pharmacy to patients at home"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3872-7447","authenticated-orcid":false,"given":"Charlotte","family":"Sikking","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.Ton","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4929-2388","authenticated-orcid":false,"given":"Mirjam","family":"Crul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0980-7743","authenticated-orcid":false,"given":"Stefan G.","family":"Romeijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"van Kesteren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke M.","family":"Beex-Oosterhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2026.104164_bib0001","unstructured":"World Health Organization. Biologicals. Available at: https:\/\/www.who.int\/health-topics\/biologicals#tab=tab_1. Accessed January 30, 2025."},{"issue":"9","key":"10.1016\/j.xphs.2026.104164_bib0002","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.xphs.2026.104164_bib0003","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejon.2019.03.003","article-title":"An observational pilot study to evaluate the feasibility and quality of oncological home-hospitalization","volume":"40","author":"Cool","year":"2019","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.xphs.2026.104164_bib0004","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1477-7525-11-163","article-title":"Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design","volume":"11","author":"Lal","year":"2013","journal-title":"Health Qual Life Outcomes"},{"issue":"1\u20132","key":"10.1016\/j.xphs.2026.104164_bib0005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.hjdsi.2016.04.004","article-title":"Home infusion: safe, clinically effective, patient preferred, and cost saving","volume":"5","author":"Polinski","year":"2017","journal-title":"Healthc (Amst)"},{"issue":"4","key":"10.1016\/j.xphs.2026.104164_bib0006","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s11095-014-1541-x","article-title":"Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics","volume":"32","author":"Ahmadi","year":"2015","journal-title":"Pharm Res"},{"issue":"4","key":"10.1016\/j.xphs.2026.104164_bib0007","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.xphs.2022.12.027","article-title":"Impact of stress on the immunogenic potential of Adalimumab","volume":"112","author":"Heljo","year":"2023","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2026.104164_bib0008","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4161\/mabs.22066","article-title":"Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice","volume":"4","author":"Filipe","year":"2012","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.xphs.2026.104164_bib0009","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1039\/D1CB00067E","article-title":"Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies","volume":"2","author":"Lundahl","year":"2021","journal-title":"RSC Chem Biol"},{"issue":"6","key":"10.1016\/j.xphs.2026.104164_bib0010","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.xphs.2017.02.029","article-title":"Potential issues with the handling of biologicals in a hospital","volume":"106","author":"Jiskoot","year":"2017","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2026.104164_bib0011","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.xphs.2018.04.005","article-title":"Postproduction handling and administration of protein pharmaceuticals and potential instability issues","volume":"107","author":"Nejadnik","year":"2018","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.xphs.2026.104164_bib0012","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.xphs.2023.05.002","article-title":"Current industry best practice on In-use stability and compatibility studies for biological products","volume":"112","author":"Blumel","year":"2023","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104164_bib0013","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.xphs.2022.01.011","article-title":"Stress factors in primary packaging, transportation and handling of protein drug products and their impact on product quality","volume":"111","author":"Narhi","year":"2022","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2026.104164_bib0014","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.xphs.2019.10.064","article-title":"Shocking data on parcel shipments of protein solutions","volume":"109","author":"Siska","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104164_bib0015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.biochi.2020.08.019","article-title":"Antibody stability: a key to performance - analysis, influences and improvement","volume":"177","author":"Ma","year":"2020","journal-title":"Biochimie"},{"issue":"8","key":"10.1016\/j.xphs.2026.104164_bib0016","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1007\/s11095-010-0143-5","article-title":"Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis","volume":"27","author":"Wang","year":"2010","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2026.104164_bib0017","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jps.24259","article-title":"Do not drop: mechanical shock in vials causes cavitation, protein aggregation, and particle formation","volume":"104","author":"Randolph","year":"2015","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.xphs.2026.104164_bib0018","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1002\/jps.21328","article-title":"Shaken, not stirred: mechanical stress testing of an IgG1 antibody","volume":"97","author":"Kiese","year":"2008","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104164_bib0019","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.xphs.2016.11.021","article-title":"Shipping-induced aggregation in therapeutic antibodies: utilization of a scale-down model to assess degradation in monoclonal antibodies","volume":"106","author":"Fleischman","year":"2017","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2026.104164_bib0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.xphs.2016.10.015","article-title":"Synergistic effect of cavitation and agitation on protein aggregation","volume":"106","author":"Torisu","year":"2017","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2026.104164_bib0021","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.xphs.2024.03.011","article-title":"Shock and temperature monitoring during transport of immunoglobulins from a hospital to patients' Homes: a pilot study","volume":"113","author":"Susam","year":"2024","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2026.104164_bib0022","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.10268","article-title":"Comparison of adverse events among home- vs Facility-administered biologic infusions, 2007-2017","volume":"4","author":"Baker","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.xphs.2026.104164_bib0023","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.14309\/ajg.0000000000000750","article-title":"Home infliximab infusions are associated with suboptimal outcomes without cost savings in inflammatory bowel diseases","volume":"115","author":"Giese-Kim","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.xphs.2026.104164_bib0024","doi-asserted-by":"crossref","first-page":"otab063","DOI":"10.1093\/crocol\/otab063","article-title":"Home infusions for inflammatory bowel disease are safe: US experience and patient perspectives","volume":"3","author":"Kochar","year":"2021","journal-title":"Crohns Colitis"},{"issue":"9","key":"10.1016\/j.xphs.2026.104164_bib0025","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/ibd\/izad226","article-title":"Adverse events and compliance among inflammatory bowel disease patients treated with home- vs office-based biologic infusions","volume":"30","author":"Schmoyer","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.xphs.2026.104164_bib0026","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/acn3.51745","article-title":"Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis","volume":"10","author":"Barrera","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.xphs.2026.104164_bib0027","unstructured":"European Directorate for the Quality of Medicines. European Pharmacopoeia 11th ed., Chapter 2.9.20: Particulate Contamination: Visible Particles. Strasbourg: Council of Europe; 2023."},{"issue":"3","key":"10.1016\/j.xphs.2026.104164_bib0028","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-010-9205-1","article-title":"Micro-flow imaging: flow microscopy applied to sub-visible particulate analysis in protein formulations","volume":"12","author":"Sharma","year":"2010","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.xphs.2026.104164_bib0029","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.xphs.2018.08.006","article-title":"Collaborative study for analysis of subvisible particles using flow imaging and light obscuration: experiences in Japanese biopharmaceutical consortium","volume":"108","author":"Kiyoshi","year":"2019","journal-title":"J Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926000134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926000134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:33:55Z","timestamp":1772721235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926000134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0022354926000134"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104164","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of the formation of (sub)visual particles in ready-to-administer trastuzumab infusion bags during transport from the hospital pharmacy to patients at home","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}],"article-number":"104164"}}